The Effect of a Cranberry Beverage on Intestinal Permeability and Gastrointestinal Function in Generally Healthy Adults

NCT ID: NCT03957239

Last Updated: 2020-01-07

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 43 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-09-05
• Study Completion Date: 2020-01-02

Brief Summary

In this double blind, crossover study participants will consume a cranberry beverage and a cranberry-flavored beverage for 2 weeks each. Gut permeability will be assessed weekly using aspirin and food-grade sugar molecules. Participants will be asked to provide urine, blood, saliva and stool samples to assess gut permeability and microbial communities. No change in permeability to the small sugar probes is anticipated with the cranberry beverage

Detailed Description

Obesity, stress, liver disease, alcoholism, diabetes, and autoimmune diseases in humans or animal models are associated with altered intestinal permeability; consequently, maintenance of the gastrointestinal barrier is an emerging area of interest. The purpose of this randomized, double-blind, controlled crossover study is to compare the difference between the change from baseline in gastroduodenal permeability after drinking a cranberry or control beverage for two weeks. Gastroduodenal permeability will be assessed following aspirin challenge by measuring urinary sucrose in the 0 to 5-hour urine collection after differential sugar probes are consumed. Urine will be collected for an additional 19 hours (24 hours total) to assess whole gut permeability. A 4-week washout period will separate the interventions. Stool and fasting blood and saliva samples will be obtained before and during the intervention periods to assess fecal microbial communities and markers of intestinal barrier, immune function and oxidative stress. It is anticipated that cranberry juice will selectively increase intestinal Akkermansia bacteria, reduce markers of inflammation and oxidative stress, increase mucosal immunity, and protect the gastroduodenal barrier from an aspirin challenge.

Conditions

Intestinal Permeability; Gastrointestinal Function

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: TRIPLE

Study Groups

Cranberry Beverage

Four prepackaged juice boxes (4.23 oz each) containing a whole milled cranberry beverage for 2 weeks

Group Type: EXPERIMENTAL

Cranberry Beverage

Intervention Type: OTHER

The cranberry beverage will provide 50 kcals and 4.0 grams of fiber per day from whole milled cranberries, water, cranberry natural flavor and sucralose.

Placebo Group

Four prepackaged juice boxes (4.23 oz each) containing a cranberry-flavored beverage for 2 weeks

Group Type: PLACEBO_COMPARATOR

Control Beverage

Intervention Type: OTHER

The control beverage will provide 50 kcals per day and is a color, taste matched sugar sweetened beverage formulated with water, sucrose, citric acid, cranberry natural flavor, malic acid, xanthum gum, sucralose and artificial color (red 40, blue 1).

Interventions

Cranberry Beverage

The cranberry beverage will provide 50 kcals and 4.0 grams of fiber per day from whole milled cranberries, water, cranberry natural flavor and sucralose.

Intervention Type: OTHER

Control Beverage

The control beverage will provide 50 kcals per day and is a color, taste matched sugar sweetened beverage formulated with water, sucrose, citric acid, cranberry natural flavor, malic acid, xanthum gum, sucralose and artificial color (red 40, blue 1).

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Have a BMI ≥ 30 kg/m2 and a waist circumference ≥ 35 inches for women and ≥ 40 inches for men.
• Have had a stable weight for 3 months (<5 kg or ~11 lbs body weight change)
• Willing to discontinue the use of non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, aspirin, naproxen, or indomethacin, for the full length of the study.
• Willing to discontinue consumption of wine and berries throughout the 12-week study.
• Willing and able to avoid consumption of any cranberry juice, whole cranberries, and dried cranberries during the two weeks leading up to the study and during the study, not including the study beverage.
• Willing to avoid beer and cocktails on the day before and the day of the sugar probe tests.
• Willing to avoid the use of antidiarrheal or laxative medication on a regular or an "as-needed basis" during the full length of the study.
• Willing to provide urine, saliva, blood, and stool samples during the study collection periods.
• Have used aspirin in the past and did not experience adverse effects.
• Willing to consume three tablets (325 mg each or 975 mg total) twice within a 9 to 12-hour period. This challenge will be repeated four times during the 12-week study.
• Willing and able to complete daily and weekly questionnaires online regarding dietary intake and general health and well-being, including gastrointestinal habits.
• Willing to discontinue consumption of fermented foods or probiotics.
• Willing to discontinue consumption of fiber supplements.
• Willing to discontinue taking prebiotic, herbal, or high-dose vitamin or mineral supplements that may impact immune function or inflammation during the pre-baseline period and throughout the study protocol.
• Willing and able to consume 4.23 oz of a cranberry beverage four times daily (~16 oz total/d) for the 2-week study interventions.
• Willing to avoid high intensity exercises two days prior to and the day of the permeability tests. These tests will be done on four occasions.
• Willing and able to complete the informed consent form in English.
• Willing to provide a social security number to receive study payment.

Exclusion Criteria

• Currently being treated for a physician-diagnosed gastrointestinal disease or condition (such as ulcerative colitis, Crohn's disease, gastroparesis, cancer, peptic ulcer disease, Celiac disease, short bowel disease, ileostomy, or colostomy) other than GERD or diverticular disease
• Currently being treated for or type 1 diabetes or type 2 diabetes by medication
• Daily use of NSAIDs in the last 3 months or incidental use in the last 2 weeks prior to screening.
• Allergy to aspirin or cranberries.
• Participate in moderate or high exercise activities during a typical week.
• Currently smoking (including vaping) tobacco products
• Women who are lactating, pregnant, or are attempting to get pregnant.
• Use of another investigational product within 3 months of the screening visit.

• Minimum Eligible Age: 21 Years
• Maximum Eligible Age: 50 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Ocean Spray, Inc.

INDUSTRY

Sponsor Role: collaborator

University of Florida

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Bobbi Langkamp-Henken, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Florida

Locations

UF Health at the University of Florida

Gainesville, Florida, United States

Countries

United States

Other Identifiers

OCR21702

Identifier Type: OTHER

Identifier Source: secondary_id

IRB201901253

Identifier Type: -

Identifier Source: org_study_id